ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of a new investigational drug,
ATX-101, for the treatment of dedifferentiated liposarcoma (LPS) and leiomyosarcoma (LMS).
ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA
with a number of "stress response" proteins. These interactions are thought to be important
for cancer cell survival and growth. ATX-101 may disrupt these interactions and therefore
help treat the cancer. In this study, all patients will receive the same treatment. Most of
the exams, tests, and procedures are part of the usual approach to medical care for this
condition. However, some additional tests or procedures may be performed, and other tests may
be performed more frequently than usual.